Gail J. Maderis, MBA
Gail J. Maderis, MBA, has served as President and Chief Executive Officer of Antiva Biosciences, a venture-funded biopharma company developing topical therapies to treat the precancerous lesions caused by human papillomavirus (HPV), since 2015. From 2009 to 2015, Ms. Maderis led BayBio, the industry organization representing and supporting Northern California’s life science community. From 2003 to 2009, Ms. Maderis served as President and Chief Executive Officer of Five Prime Therapeutics, Inc., a protein discovery and development company. Prior to FivePrime, Gail held senior executive positions at Genzyme Corporation, including Founder and President of Genzyme Molecular Oncology. Ms. Maderis also practiced management and strategy consulting with Bain & Co. She serves on the corporate boards of Allarity Therapeutics and Valitor, Inc., as well as on the nonprofit boards of BIO (Emerging Company and Health Sections), Clinical and Laboratory Standards Institute (CLSI), The Termeer Foundation, and the University of California Berkeley Foundation Board of Trustees. She received a Bachelor of Science in business from the University of California at Berkeley and a Master of Business Administration from Harvard Business School.